Akshat Jain/Photo:
lluh.org
Apr 22, 2026, 07:40
Akshat Jain: WIL33 Study Advances Factor Prophylaxis in Children with von Willebrand Disease
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn:
”It was wonderful presenting our research on factor prophylaxis for Children with Von Willebrand Disease at the WFH 2026 congress.
How we treat VWD especially in young children remain undetermined in the absence of robust clinical trials and medications that always are late to arrive for pediatric indications.
Through the WIL33 study (7 country, 3 continents ) that I had the honor to lead for Octapharma this gap has been addressed and real world care can start to be defined to assist clinicians world over.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 08:17Maha Othman: Celebrating Research and Collaboration at the Sinclair Cancer Research Institute 2026 Annual Retreat
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation